Compugen (CGEN) Director Anat Cohen-Dayag Receives 100,000-Share Award

What Happened Anat Cohen‑Dayag, a director of Compugen Ltd. (CGEN), was granted a derivative award covering 100,000 shares on July 29, 2026. The Form 4 reports an acquisition value of $0 for the award (derivative instrument). This is a grant of equity compensation rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-07-29; reported on Form 4 filed 2026-07-30 (timely filing).
• Reported acquisition: 100,000 shares (derivative grant) at $0.00 reported price.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Vesting (footnote): 25% vests on Sept 30, 2027; remaining 75% vests in 12 equal quarterly installments thereafter, subject to continued service.
• No indication in this filing that shares were sold or immediately exercised.

Context This filing documents an equity award (option or similar derivative) granted as compensation/retention for a director. Such grants do not represent immediate market purchases or sales and should be viewed as part of executive/director pay rather than a direct trading signal. The exercise price (if any) is not specified in the excerpt.